ARGX-110 AML/TCL workshop at ASH, webcast replay, Atlanta

argenx in short

argenx combines the diversity of the llama immune system with antibody engineering advancing a clinical pipeline to treat patients with cancer and severe autoimmune diseases. Our platforms allow us to unlock novel and complex targets and develop antibody-based drugs designed for greater efficacy and longer duration of effect.

Human antibodies for novel targets and underserved diseases

argenx develops product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. This is enabled by our suite of differentiated technologies. Our SIMPLE Antibody™ Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates.  

Product pipeline

argenx creates antibodies with first- and best-in-class therapeutic potential. We have a deep pipeline of differentiated antibody-based therapies with one autoimmune asset in clincal phase, two potential oncology drugs in the clinic and several product leads in preclinical development.  

ONCOLOGY AUTOIMMUNITY

Read more

Partnering opportunities

Collaboration agreements with pharmaceutical companies enable argenx to provide our expertise to our partners and develop therapeutic antibody candidates in multiple disease areas. We are also accessing truly novel targets through partnerships with academic research groups under our Innovative Access Program. 

PARTNERSHIPS INNOVATIVE ACCESS PROGRAM

Read more